{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-005156","form_type":"8-K","ticker":"PBYI","cik":"0001401667","company_name":"PUMA BIOTECHNOLOGY, INC.","filed_at":"2022-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.300525+00:00","generated_at":"2026-06-27T01:55:57.696765+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Puma Q4 net income $4.2M vs loss; FY loss narrows to $29.1M from $60.0M","bullets":["Q4 product revenue $51.0M (+2% YoY); total revenue $55.4M including $1.5M license and $2.9M royalty.","GAAP net income Q4 $4.2M ($0.10 EPS) vs loss of $15.0M ($0.38 loss) in Q4 2020.","FY 2021 net loss $29.1M ($0.72 loss) vs $60.0M loss ($1.52 loss); non-GAAP adjusted net income $3.5M.","Cash and securities $82.1M at Dec 31; operating cash flow $20.7M provided in FY 2021 vs $0.8M in FY 2020.","Key 2022 catalysts: pre-NDA meeting for neratinib HER2-mutant breast cancer, Phase II data in multiple indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-005156","json":"https://secwatch.observer/filing/0001437749-22-005156.json","markdown":"https://secwatch.observer/filing/0001437749-22-005156.md","text":"https://secwatch.observer/filing/0001437749-22-005156.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401667/000143774922005156/0001437749-22-005156-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401667/000143774922005156/pbyi20220228_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T01:55:57.696765+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}